These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22718623)

  • 1. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
    Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
    Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders.
    Gassó P; Mas S; Alvarez S; Trias G; Bioque M; Oliveira C; Bernardo M; Lafuente A
    Pharmacogenomics; 2010 Dec; 11(12):1725-31. PubMed ID: 21142916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
    Tennezé L; Tarral E; Ducloux N; Funck-Brentano C
    Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese.
    Li D; Abudula A; Abulahake M; Zhu AP; Lou YQ; Zhang GL
    J Clin Pharmacol; 2010 Jul; 50(7):775-84. PubMed ID: 20160155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
    Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
    Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.
    Noetzli M; Guidi M; Ebbing K; Eyer S; Zumbach S; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
    Ther Drug Monit; 2013 Apr; 35(2):270-5. PubMed ID: 23503455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population.
    Salameh G; Al Hadidi K; El Khateeb M
    Environ Toxicol Pharmacol; 2012 Jul; 34(1):23-33. PubMed ID: 22426036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
    Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Br J Clin Pharmacol; 2009 Jul; 68(1):89-96. PubMed ID: 19660006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.